Category - Markets

Leerink raised its price target for resTORbio (NASDAQ:TORC) to $45 from $35 after the company announced positive top-line results from its Phase 2b clinical trial of RTB101. The stock finished at $13.47 on July 25. The...

Alliance Global Partners launched coverage of Profound Medical (OTCQX:PRFMF; TSX:PRN) with a “buy” rating and price target of $1.60. The stock closed at 70 cents on July 24. Analyst Ben Haynor writes that the...

Canaccord Genuity initiated coverage of Neuronetics (NASDAQ:STIM) with a “buy” rating and $33 price target. The stock closed at $26.02 on July 23. “Possessing a clinically validated, proprietary, non-invasive technology...

Roth Capital Partners launched coverage of Menlo Therapeutics (NASDAQ:MNLO) with a “buy” rating and $29 price target. The stock finished at $7.50 on July 23. Yasmeen Rahimi writes that the company has a Phase 3 asset...

Canaccord Genuity initiated coverage of Profound Medical (TSX:PRN; OTCQX:PRFMF) with a “buy” rating and price target of $2. The stock closed at 94 cents on July 23. “Profound Medical has the makings of an exciting med...

Analysts at Piper Jaffray, William Blair and BTIG launched coverage of Neuronetics (NASDAQ:STIM) with “overweight, outperform and buy” ratings, respectively. The stock closed at $26.53 on July 20. “Although the company...

Leerink initiated coverage of Translate Bio (NASDAQ:TBIO) with an “outperform” rating and $24 price target. The stock closed at $15.94 on July 20. Translate Bio is developing MRT5005, a messenger RNA (mRNA)-based...

H.C. Wainwright slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $16 from $33 after the company disclosed a partial clinical hold on its lead clinical program targeting HER2 expressing cancers. The...

H.C. Wainwright initiated coverage of Innovate Biopharmaceuticals (NASDAQ:INNT) with a “buy” rating and $35 price target. The stock finished at $8.08 on July 17. Innovate is focused on two clinical-stage assets aimed at...

William Blair launched coverage of Autolus Therapeutics (NASDAQ:AUTL) with an “outperform” rating and risk-adjusted valuation of roughly $38. The stock closed at $20.86 on July 17. “Based on our view, the company’s next...